Kidney fibrosis: origins and interventions

T Vanhove, R Goldschmeding, D Kuypers - Transplantation, 2017 - journals.lww.com
All causes of renal allograft injury, when severe and/or sustained, can result in chronic
histological damage of which interstitial fibrosis and tubular atrophy are dominant features …

[HTML][HTML] Renal allograft fibrosis: biology and therapeutic targets

P Boor, J Floege - American journal of transplantation, 2015 - Elsevier
Renal tubulointerstitial fibrosis is the final common pathway of progressive renal diseases. In
allografts, it is assessed with tubular atrophy as interstitial fibrosis/tubular atrophy (IF/TA) …

[HTML][HTML] Polyclonal regulatory T cell therapy for control of inflammation in kidney transplants

S Chandran, Q Tang, M Sarwal, ZG Laszik… - American Journal of …, 2017 - Elsevier
Early subclinical inflammation in kidney transplants is associated with later graft fibrosis and
dysfunction. Regulatory T cells (Tregs) can reverse established inflammation in animal …

[HTML][HTML] Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant

JJ Friedewald, SM Kurian, RL Heilman… - American Journal of …, 2019 - Elsevier
Noninvasive biomarkers are needed to monitor stable patients after kidney transplant (KT),
because subclinical acute rejection (subAR), currently detectable only with surveillance …

[HTML][HTML] Kidney allograft survival after acute rejection, the value of follow-up biopsies

M El Ters, JP Grande, MT Keddis, E Rodrigo… - American journal of …, 2013 - Elsevier
Kidney allografts are frequently lost due to alloimmunity. Still, the impact of early acute
rejection (AR) on long-term graft survival is debated. We examined this relationship focusing …

[HTML][HTML] High intrapatient variability of tacrolimus concentrations predicts accelerated progression of chronic histologic lesions in renal recipients

T Vanhove, T Vermeulen, P Annaert, E Lerut… - American Journal of …, 2016 - Elsevier
High intrapatient variability (IPV) of tacrolimus concentrations is increasingly recognized as
a predictor of poor outcome in solid organ recipients. How it relates to evolution of histology …

[HTML][HTML] Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: a randomized controlled trial

S Chandran, J Leung, C Hu, ZG Laszik, Q Tang… - American Journal of …, 2021 - Elsevier
Interleukin-6 (IL-6) is a proinflammatory cytokine and key regulator of Treg: T effector cell
(Teff) balance. We hypothesized that IL-6 blockade with tocilizumab, a monoclonal antibody …

[HTML][HTML] Transplanting kidneys from deceased donors with severe acute kidney injury

RL Heilman, ML Smith, SM Kurian, J Huskey… - American Journal of …, 2015 - Elsevier
Our aim was to determine outcomes with transplanting kidneys from deceased donors with
acute kidney injury, defined as a donor with terminal serum creatinine≥ 2.0 mg/dL, or a …

[HTML][HTML] Reduction of extended-release tacrolimus dose in low-immunological-risk kidney transplant recipients increases risk of rejection and appearance of donor …

P Gatault, N Kamar, M Büchler, C Colosio… - American Journal of …, 2017 - Elsevier
The aim of this study (ClinicalTrials. gov, NCT01744470) was to determine the efficacy and
safety of two different doses of extended-release tacrolimus (TacER) in kidney transplant …

[HTML][HTML] Gene expression in biopsies of acute rejection and interstitial fibrosis/tubular atrophy reveals highly shared mechanisms that correlate with worse long‐term …

BD Modena, SM Kurian, LW Gaber, J Waalen… - American Journal of …, 2016 - Elsevier
Interstitial fibrosis and tubular atrophy (IFTA) is found in approximately 25% of 1‐year
biopsies posttransplant. It is known that IFTA correlates with decreased graft survival when …